# A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

> **NCT07145918** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 268 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Emraclidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07145918
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145918, "A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07145918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*